This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia
Signal Transduction and Targeted Therapy Open Access 15 September 2021
-
Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia
Leukemia Open Access 07 November 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007; 2: 58–61.
Hendriks RW, Yuvaraj S, Kil LP . Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer 2014; 14: 219–232.
Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 2014; 123: 1207–1213.
de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590–2594.
Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877–1964.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.
Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011; 13: R115.
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075–13080.
Gao W, Wang M, Wang L, Lu H, Wu S, Dai B et al. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst 2014; 106; doi: 10.1093/jnci/dju204.
Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ . Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 2014; 123: 1229–1238.
Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984–3076.
Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 2011; 7: 41–50.
Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther 2013; 346: 219–228.
Quentmeier H, MacLeod RA, Zaborski M, Drexler HG . JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20: 471–477.
Oellerich T, Mohr S, Corso J, Beck J, Dobele C, Braun H et al. FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation. Blood 2015; 125: 1936–1947.
Kayser S, Levis MJ . FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leuk Lymphoma 2014; 55: 243–298.
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-Cell malignancies. J Clin Oncol 2013; 31: 88–94.
Acknowledgements
JL, QL and WW are supported by the grant of ‘Cross-disciplinary Collaborative Teams Program for Science, Technology and Innovation (2014-2016)’ from Chinese Academy of Sciences. ZZ is supported by Anhui Province Natural Science Foundation Annual Key Program (grant number: 1301023011). We thank China ‘Thousand Talents Program’ support for QL and ‘Hundred Talents Program’ of The Chinese Academy of Sciences support for JL and WW.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Wu, H., Hu, C., Wang, A. et al. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 30, 754–757 (2016). https://doi.org/10.1038/leu.2015.175
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.175
This article is cited by
-
Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia
Signal Transduction and Targeted Therapy (2021)
-
Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia
Leukemia (2018)
-
MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia
Leukemia (2017)
-
Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML
Leukemia (2016)